Corrigendum to “Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis”. [J. Affect. Disord., 322 (2023), 194–204]
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare, James Rucker
Journal of Affective Disorders January 5, 2024 correction DOI: 10.1016/j.jad.2023.10.159 via OpenAlex
Study at a glance
| Topics | Anxiety |
|---|---|
| Keywords | Affect linguistics Clinical psychology Depressive symptoms Psychotherapist Psychiatry |
| Citations | 1 |
| Key finding | Corrected results show psilocybin produced marked reductions in depression scores at 1 week, 5 weeks, and 3 months, with a 45% response rate and 20% remission rate at 5 weeks. |
Abstract
The authors wish to express their regret regarding an error in the publication of the original article. In Table 3, titled “Psilocybin studies on depressive disorders,” specifically in the fourth row related to the study conducted by Carhart-Harris et al. (2016), the main results column inaccurately presented the Cohen's d figure, which included data from Carhart-Harris et al. (2018) that pertained to eight additional participants, data which were not analyzed in Carhart-Harris et al. (2016). For the sake of clarity and accuracy, the corrected version should read as follows: 1-week: marked reduction in QIDS (Hedges' g = 3.1, p = .002) 5-week: marked reduction in QIDS (Hedges' g = 2.7, p = .003); response and remission rate at 45 % and 20 % 3-month: reduction in QIDS remained positive (Hedges' g = 2.0, p = .003). The authors would like to apologise for any inconvenience caused.